Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.: 9–10
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | 2026-02-17 17:01:38 | 4.31 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCEL | 0001762303 | AVITA Medical, Inc. | US05380C1027 | 5299003E8ETEQDDQ3826 | 202578762 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 28159 AVENUE STANFORD | VALENCIA | CA | 91355 | UNITED STATES | US | 661-568-1317 | 28159 AVENUE STANFORD, VALENCIA, CA, 91355 | 28159 AVENUE STANFORD, VALENCIA, CA, 91355 | Avita Therapeutics, Inc. | Regenerative medicine | 1993 | — | — | http://www.avitamedical.com | 203,434,831 | 30,493,111 | 30,493,111 | Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa (EMEA) and Australia.: 9–10 | 2026-02-12 20:06:42 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 138,669,045 | -64,765,786 | -31.8361 | 30,631,794 | 4,274,252 | 16.2164 |
| 2024 | 203,434,831 | -228,426,191 | -52.8934 | 26,357,542 | 650,880 | 2.532 |
| 2023 | 431,861,022 | 314,399,984 | 267.6632 | 25,706,662 | 410,576 | 1.6231 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Donna Shiroma | General Counsel | 2024 | 229,072 | 113,250 | — | — | 491,541 | 1,688,796 |
| David O'Toole | Chief Financial Officer | 2024 | 459,253 | 195,500 | — | — | 54,109 | 1,777,528 |
| James Corbett | Chief Executive Officer | 2024 | 684,231 | 459,000 | — | — | 20,487 | 3,243,885 |
| Donna Shiroma | General Counsel | 2023 | 431,526 | 209,829 | 0 | — | 47,249 | 1,236,104 |
| James Corbett | Chief Financial Officer, Chief Executive Officer | 2023 | 625,000 | 491,188 | 0 | — | 39,987 | 2,068,675 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 226 |
| 2024 | 260 |
| 2023 | 207 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 71,610,000 | 64,251,000 | 50,143,000 |
| Cost Of Revenue | 12,794,000 | 9,094,000 | 7,780,000 |
| Gross Profit | 58,816,000 | 55,157,000 | 42,363,000 |
| Research And Development Expenses | 20,839,000 | 20,360,000 | 20,821,000 |
| General And Administrative Expenses | 27,373,000 | 33,195,000 | 28,334,000 |
| Operating Expenses | 101,350,000 | 111,750,000 | 86,446,000 |
| Operating Income | -42,534,000 | -56,593,000 | -42,655,000 |
| Net Income | -48,587,000 | -61,845,000 | -35,381,000 |
| Earnings Per Share Basic | -1.74 | -2.39 | 1.4 |
| Earnings Per Share Diluted | -1.74 | -2.39 | 1.4 |
| Weighted Average Shares Outstanding Basic | 27,860,784 | 25,883,056 | 25,331,264 |
| Weighted Average Shares Outstanding Diluted | 27,860,784 | 25,883,056 | 25,331,264 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 10,243,000 | 14,050,000 | 22,118,000 |
| Marketable Securities Current | 7,942,000 | 21,835,000 | 66,939,000 |
| Accounts Receivable | 9,086,000 | 11,786,000 | 7,664,000 |
| Inventories | 6,926,000 | 7,269,000 | 5,596,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | 18,000 |
| Total Assets Current | 35,490,000 | 57,000,000 | 104,006,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 8,630,000 | 10,018,000 | 1,877,000 |
| Other Assets Non Current | 612,000 | 546,000 | 355,000 |
| Total Assets Non Current | 20,902,000 | 22,711,000 | 7,634,000 |
| Total Assets | 56,392,000 | 79,711,000 | 111,640,000 |
| Accounts Payable | 8,959,000 | 6,294,000 | 3,793,000 |
| Deferred Revenue | 33,000 | 33,000 | 33,000 |
| Short Term Debt | 42,984,000 | — | — |
| Other Liabilities Current | 2,645,000 | 1,319,000 | 1,266,000 |
| Total Liabilities Current | 62,677,000 | 20,158,000 | 13,199,000 |
| Long Term Debt | 0 | 42,245,000 | 39,812,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 10,365,000 | 54,810,000 | 48,692,000 |
| Total Liabilities | 73,042,000 | 74,968,000 | 61,891,000 |
| Common Stock | 3,000 | 3,000 | 3,000 |
| Retained Earnings | -408,401,000 | -359,814,000 | -297,969,000 |
| Accumulated Other Comprehensive Income | -1,367,000 | -1,939,000 | -1,887,000 |
| Total Shareholders Equity | -16,650,000 | 4,499,000 | 49,056,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 2,347,000 | 1,126,000 | 632,000 |
| Share Based Compensation Expense | 9,519,000 | 13,496,000 | 8,384,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | 468,000 | 2,160,000 | 3,693,000 |
| Change In Non Trade Receivables | — | 26,000 | -868,000 |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,745,000 | 340,000 | 809,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -31,195,000 | -48,939,000 | -38,011,000 |
| Purchases Of Marketable Securities | 13,309,000 | 24,504,000 | 78,757,000 |
| Sales Of Marketable Securities | 27,500,000 | 71,200,000 | 2,372,000 |
| Acquisition Of Property Plant And Equipment | 1,005,000 | 9,171,000 | 1,381,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 12,452,000 | 37,363,000 | 1,607,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 14,792,000 | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | 38,762,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 14,936,000 | 3,508,000 | 40,374,000 |
| Change In Cash | -3,807,000 | -8,068,000 | 3,954,000 |
| Cash At End Of Period | 10,243,000 | 14,050,000 | 22,118,000 |
| Income Taxes Paid | 15,000 | 41,000 | 44,000 |
| Interest Paid | 4,980,000 | 5,359,000 | 1,143,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.74 | -2.39 | 1.4 |
| Price To Earnings Ratio | -1.9828 | -5.3556 | 9.8 |
| Earnings Growth Rate | -27.1967 | -270.7143 | 30.8411 |
| Price Earnings To Growth Ratio | 0.0729 | 0.0198 | 0.3178 |
| Book Value Per Share | -0.5976 | 0.1832 | 1.9639 |
| Price To Book Ratio | -5.773 | 69.851 | 6.986 |
| Ebitda | -41,221,000 | -55,317,000 | -33,562,000 |
| Enterprise Value | 128,860,704.8 | 359,498,116.8 | 365,238,942.08 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -2.5816 | 9.3899 | 0.8116 |
| Capital Expenditures | 959,000 | 9,267,000 | 1,309,000 |
| Free Cash Flow | -32,154,000 | -58,206,000 | -39,320,000 |
| Return On Equity | 2.9181 | -13.7464 | -0.7212 |
| One Year Beta | 1.1344 | 1.6801 | 1.6114 |
| Three Year Beta | 1.372 | 1.5009 | 1.4784 |
| Five Year Beta | 1.4086 | 1.5289 | 1.5447 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| McNamara Robert | Director | 2025-08-28 | 10,000 | A | 86,771 |
| O'Toole David D | CFO | 2025-08-26 | 2,000 | A | 31,657 |
| McNamara Robert | Director | 2025-08-19 | 10,000 | A | 76,771 |
| O'Toole David D | CFO | 2025-08-12 | 2,000 | A | 29,657 |
| O'Toole David D | CFO | 2025-05-30 | 1,923 | A | 27,657 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| AQR CAPITAL MANAGEMENT LLC | 2025-12-31 | 350,148 | 101,492 | 3.45 |
| Jain Global LLC | 2025-12-31 | 83,380 | 24,168 | 3.45 |
| CITADEL ADVISORS LLC | 2025-12-31 | 74,175 | 21,500 | 3.45 |
| CITADEL ADVISORS LLC | 2025-12-31 | 69,656 | 20,190 | 3.45 |
| CITADEL ADVISORS LLC | 2025-12-31 | 126,615 | 36,700 | 3.45 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-11-30 | SIIT Extended Market Index Fund - Class A | SMXAX | 5,000 | 18,500 | 0.0015 |
| PROSHARES TRUST | 2025-11-30 | ProShares Hedge Replication ETF | HDG | 16 | 59.2 | 0.0002 |
| PROSHARES TRUST | 2025-11-30 | ProShares UltraPro Russell2000 | URTY | 949 | 3,511.3 | 0.0009 |
| PROSHARES TRUST | 2025-11-30 | ProShares Ultra Russell2000 | UWM | 747 | 2,763.9 | 0.0011 |
| PROSHARES TRUST | 2025-11-30 | ProShares Russell 2000 High Income ETF | ITWO | 357 | 1,320.9 | 0.0015 |